1 / 3

Topic 3: ACPS Questions Highly Variable Drugs

Topic 3: ACPS Questions Highly Variable Drugs. FDA/CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS). Topic 3 Question 1: . Does the committee agree with the use of a point estimate constraint when applying scaled bioequivalence? If yes, is the 80 –

monte
Télécharger la présentation

Topic 3: ACPS Questions Highly Variable Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Topic 3: ACPS Questions Highly Variable Drugs FDA/CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS)

  2. Topic 3 Question 1: Does the committee agree with the use of a point estimate constraint when applying scaled bioequivalence? If yes, is the 80 – 125% limit on the point estimate appropriate? FDA/CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS)

  3. We propose a minimum sample size of 36 subjects when evaluating the BE of highly variable drugs. Does the Committee concur? Topic 3 Question 2: FDA/CDER ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE (ACPS)

More Related